Several studies have recently been released looking at the use of dry mannitol powder in an inhalation device for the management of cystic fibrosis. One study, entitled “Optimising inhaled mannitol for cystic fibrosis in an adult population,” published in Breathe, explored the safety and effectiveness of inhaled mannitol versus a placebo and found that those who took mannitol had improvement in their cystic fibrosis symptoms.
Mannitol is an osmotic agent that, when dry and inhaled, draws fluid into the bronchial tree. This loosens the mucus in the bronchial tree so it can be more easily coughed up. Mannitol has been found to be safe in cystic fibrosis patients and effective in improving the removal of respiratory secretions, even in those patients who were maximally treated on other cystic fibrosis therapies.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management